Overexpression of EZH2 has been reported in various cancers, including breast cancer, esophageal cancer, poorly differentiated and anaplastic thyroid cancer, and several neuroendocrine cancers, where it seems to harbor an adverse prognosis [11,12,13,14,15]. Here, EZH2 is linked to breast carcinoma.